Earnings ·
Azenta raises full-year revenue guidance to $613M-$618M as Q3 sales rise 12% to $161 million
AZTAAzenta, Inc.
Azenta, Inc. reported financial results for the third quarter ended June 30, 2026, with revenue from continuing operations reaching $161 million, a 12% increase year over year. Organic growth was 9%, driven by Sample Management Solutions ($88 million) and Multiomics ($73 million). The company reported a diluted EPS of $(0.03) from continuing operations and total diluted EPS of $0.05. Adjusted EBITDA for continuing operations was $18 million, with an adjusted EBITDA margin of 11.4%. Azenta updated its full-year fiscal 2026 guidance, now expecting total reported revenue between $613 million and $618 million and Adjusted EBITDA between $59 million and $62 million. The company ended the quarter with $529 million in cash and liquidity. As of June 30, 2026, Azenta had repurchased 2.3 million shares for $50 million under its 2025 share repurchase program. Azenta is a provider of life sciences solutions, offering cold-chain sample management and multiomics services to pharmaceutical, biotech, and academic institutions.